Related Experiment Video

Updated: Jun 18, 2025

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion
09:02

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion

Published on: February 2, 2021

4.4K

Apixaban Use in Patients with Kidney Impairment: A Review of Pharmacokinetic, Interventional, and Observational Study

Stephen R Mandt1, Noble Thadathil2, Christian Klem2

  • 1Bristol Myers Squibb, Lawrenceville, NJ, USA. Stephen.Mandt@gmail.com.

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|August 5, 2024
PubMed

Insights

Direct oral anticoagulants like apixaban are effective for patients with atrial fibrillation (AF) and venous thromboembolism (VTE), even with chronic kidney disease (CKD). Apixaban demonstrates a favorable safety and efficacy profile across various kidney function levels.

Area of Science:

  • Nephrology
  • Cardiology
  • Pharmacology

Background:

  • Chronic kidney disease (CKD) is a major global health concern, increasing risks for atrial fibrillation (AF) and venous thromboembolism (VTE).
  • Direct oral anticoagulants (DOACs) are standard for anticoagulation (AC) in AF and VTE, but their use in patients with kidney impairment requires careful consideration.

Purpose of the Study:

  • To review the effectiveness and safety of apixaban in patients with renal dysfunction.
  • To assess available pharmacokinetic, interventional, observational, and guideline data on apixaban use in CKD patients.

Main Methods:

  • Narrative review of published scientific literature.
  • Assessment of pharmacokinetic data.
  • Evaluation of interventional and observational studies.
  • Analysis of clinical guidelines.

Main Results:

  • Apixaban, a direct factor Xa inhibitor, shows well-established pharmacokinetics and consistent outcomes in patients with kidney impairment.
  • Scientific literature indicates apixaban offers a favorable efficacy and safety profile compared to vitamin K antagonists for AF and VTE patients with CKD.
  • Data support apixaban's approved dosing for stroke risk reduction in nonvalvular AF and VTE treatment across all kidney function ranges.

Conclusions:

  • Apixaban is a viable anticoagulation option for patients with AF or VTE and varying degrees of kidney impairment.
  • While generally safe and effective, management of advanced CKD or dialysis patients may necessitate individualized approaches due to limited specific data.

More Related Videos

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

13.7K
Direct Drug Delivery to Kidney via the Renal Artery11:18

Direct Drug Delivery to Kidney via the Renal Artery

Published on: April 17, 2021

7.2K

Related Concept Videos

Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
68
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
77
Factors Affecting Renal Clearance: Drug's Physicochemical Properties and Plasma Levels01:31

Factors Affecting Renal Clearance: Drug's Physicochemical Properties and Plasma Levels

Renal clearance of a drug is influenced by various factors, including its physicochemical properties and plasma levels. These factors play a significant role in determining how efficiently the kidneys eliminate a drug.
One important factor is the drug's molecular size. The kidneys readily excrete smaller molecules below 300 Daltons (Da). On the other hand, molecules weighing between 300 and 500 Da are excreted through both urine and bile. Larger molecules above 500 Da tend to be excreted...
199
Factors Affecting Renal Clearance: Drug Distribution and Drug Interactions01:09

Factors Affecting Renal Clearance: Drug Distribution and Drug Interactions

Renal clearance plays a pivotal role in drug elimination from the body and can be influenced by drug distribution and interactions. Understanding these factors is crucial in pharmacology as they impact the effectiveness and duration of drug therapy.
One important factor is the relationship between renal clearance and the apparent volume of distribution. Renal clearance tends to be inversely proportional to the apparent volume of distribution. Drugs with an extensive distribution volume or those...
114
Renal Drug Excretion: Effect of Urine pH, Flow Rate, and Drug pKa01:22

Renal Drug Excretion: Effect of Urine pH, Flow Rate, and Drug pKa

The pH of urine, the drug's pKa, and the urine flow rate are vital parameters for drug reabsorption and excretion. Urinary pH varies between 4.6 and 8.0 and is influenced by diet, drug intake, and the patient's pathophysiology. It affects a drug's ionization state and reabsorption. For instance, carbohydrate-rich food produces alkaline urine promoting drug excretion, while proteins and certain medications like ascorbic acid lead to acidic urine enhancing reabsorption.
The pKa of a...
154
Renal Drug Excretion: Tubular Reabsorption01:25

Renal Drug Excretion: Tubular Reabsorption

Tubular reabsorption, a process occurring post-glomerular filtration of drugs in the renal tubule, is a critical determinant of drug half-life. During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. This...
144